Literature DB >> 2354409

Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy.

C A North1, R B North, J A Epstein, S Piantadosi, M D Wharam.   

Abstract

Of 77 patients with supratentorial Grades I and II astrocytoma diagnosed from January 1975 to December 1984, 66 were treated with postoperative radiation therapy. The patients received a tumor dose of 5000 to 5500 cGy in 180 cGy fractions, five fractions per week, over 5.5 to 6 weeks. Overall actuarial survival at 2, 5, and 10 years was 71%, 55%, and 43%, respectively. Progression-free survival at 2, 5, and 10 years was 69%, 50%, and 39%, respectively. Survival for patients receiving postoperative radiation therapy in the range of 4500 to 5900 cGy was 78% and 66% at 2 and 5 years, respectively. Quality of life was determined at two points in time: 1 to 2 years postoperatively, and at last follow-up (2-12 years postoperatively). The occurrence of mental retardation was specifically addressed in long-term survivors, and was observed in 50% of children. Overall, however, 80% of short-term survivors and 67% of long-term survivors were intellectually and physically intact, without major neurologic deficit. Specific prognostic factors were assessed by multivariate analysis. Improved survival was observed with young patients, females, normal preoperative mental status, surgical resection (versus biopsy alone), involvement of only one lobe with tumor, and a history of preoperative seizures. A weighted prognostic factor score derived from these observations permits a clinically useful assessment of risk for individual patients.

Entities:  

Mesh:

Year:  1990        PMID: 2354409     DOI: 10.1002/1097-0142(19900701)66:1<6::aid-cncr2820660103>3.0.co;2-f

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  46 in total

Review 1.  Radiation therapy for incompletely resected supratentorial low-grade glioma in adults.

Authors:  B Jeremic; M Bamberg
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

2.  Low-grade pure and mixed cerebral astrocytomas treated in the CT scan era.

Authors:  J P Bahary; J G Villemure; S Choi; R Leblanc; A Olivier; G Bertrand; L Souhami; D Tampieri; J Hazel
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

3.  Assessment of quality of life in patients treated for low-grade glioma: a preliminary report.

Authors:  M J Taphoorn; J J Heimans; F J Snoek; J Lindeboom; B Oosterink; J G Wolbers; A B Karim
Journal:  J Neurol Neurosurg Psychiatry       Date:  1992-05       Impact factor: 10.154

4.  The use of a simple Likert scale to measure quality of life in brain tumor patients.

Authors:  M P Rogers; J Orav; P M Black
Journal:  J Neurooncol       Date:  2001-11       Impact factor: 4.130

Review 5.  Pediatric low-grade gliomas.

Authors:  Angela J Sievert; Michael J Fisher
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

Review 6.  Operative techniques for gliomas and the value of extent of resection.

Authors:  Nader Sanai; Mitchel S Berger
Journal:  Neurotherapeutics       Date:  2009-07       Impact factor: 7.620

7.  Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery.

Authors:  M L van Veelen; C J Avezaat; J M Kros; W van Putten; C Vecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

8.  Proliferative activity and prognosis of low-grade astrocytomas.

Authors:  D Schiffer; P Cavalla; A Chiò; P Richiardi; M T Giordana
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 9.  Low grade gliomas: functional mapping resection strategies, extent of resection, and outcome.

Authors:  M S Berger; R C Rostomily
Journal:  J Neurooncol       Date:  1997-08       Impact factor: 4.130

Review 10.  Effect of age on treatment decisions in low-grade glioma.

Authors:  C J Vecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.